RxDoctor Payments Data

Nasir Shariff, MD

Clinical Cardiac Electrophysiology · Tacoma, WANPI 1851590525

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (41.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Biosense Webster, Inc. at 48.1% of the total.

$12,279in general payments, 2019–2025

Across 77 payments — averaging $159.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biosense Webster, Inc.$6K
  • Medtronic$3K
  • Abbott$2K
  • Boston Scientific$912
  • Livanova USA, Inc.$169
  • Kestra Medical Technology Services, Inc.$76
  • plus $31 from 2 others
$37,359in research payments, 2019–2025

Across 18 payments — averaging $2075.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$23K
  • Biosense Webster, Inc.$14K

What the payments were for

  • Consulting fees$4,12534%
  • Grants$1471%
  • Travel & lodging$5,09942%
  • Food & beverage$2,90724%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,279 in reported general payments places this provider in the 60th percentile of 68 clinical cardiac electrophysiology providers in Washington.

See all clinical cardiac electrophysiology providers in Washington

Medicare billing

Part B allowed, 2024
$490,542
Medicare patients
1,299
Services billed
4,686

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban122$134,998
EliquisApixaban114$123,219
Dofetilide14$7,265
Metoprolol Succinate209$4,002
Flecainide Acetate28$1,146
Amiodarone Hcl93$1,007
Diltiazem 24hr Er (Cd)Diltiazem Hcl18$470
ClopidogrelClopidogrel Bisulfate25$331
Pantoprazole Sodium66$324
Carvedilol34$263
Losartan Potassium15$234
Metoprolol Tartrate47$139

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$18$134,998122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 68 clinical cardiac electrophysiology providers in Washington.

Other clinical cardiac electrophysiology in Tacoma

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →